अनुस लेबोरेटरीज > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का अनुस लेबोरेटरीज - बीएसई: 532981, NSE: N.A

अनुस लेबोरेटरीज

बीएसई: 532981  |  NSE: N.A  |  ISIN: INE450H01022  |  Pharmaceuticals

कंपनी इतिहास - अनुस लेबोरेटरीज
Our Company was incorporated in the year 1996 for manufacture of Bulk
 Pharma Ingredients and Intermediates for drug molecules and was
 promoted by 
 Mr. K. Hari Babu. Mr. N.S. Walimbe joined as copromoter in the year
 Our Company was not having its own manufacturing facilities initially
 and utilized 
 premises and production facilities of Dr. Curies Labs Limited for a
 period of two 
 years till 1998 under leave and license agreement, which terminated
 in September, 
 1998. At this facility our Company manufactured 2,4 Dichloro 5 Fluoro
 (DCFA) a drug intermediate for manufacture of Quinolones, which we
 supplied to 
 Dr. Reddys Laboratories Limited and Aurobindo Pharma Limited.
 In July 14, 1998 an agreement for sale was entered into by our
 Company with Andhra 
 Pradesh Industrial Development Corporation (APIDC) and Andhra Pradesh
 Financial Corporation (APSFC) to purchase land, buildings and plant &
 machinery of 
 M/s Jay Organics Limited situated at Survey No. 17, Chilakamarri
 Village, Shadnagar, 
 Mahboobnagar District, Andhra Pradesh under Section 29 of the SFC
 Act, 1952. M/s Jay
 Organics Limited had defaulted in payment of loans to its lenders /
 these Corporations and 
 in exercise of power under Section 29 of the SFC Act, 1952, the
 lenders advertised the 
 sale of this unit and our Company offered to purchase this land,
 building and plant & 
 machineries for a total consideration of Rs. 40.40 lakhs. On
 acquisition of these facilities 
 we started our own manufacturing facilities.  
 Further with a view to add more products in our product profile we
 entered into contracts 
 in 2004 with Nitya Laboratories Limited for conversion jobs for
 manufacture of Sodium 
 Methoxide or Sodium Methylate Solution & Powder and CIS (+) Hydroxy
 Lactum. Sodium 
 Methoxide and CIS Lactum contributed 9.73% and 24.27% respectively
 during nine months 
 period ended December 31, 2007 in our total sales. For details of
 contracts, please refer 
 to paragraph Other Agreements appearing on page number 95 of this Red
 We are engaged in manufacture of Basic & Advanced Intermediates and
 fine chemicals 
 and are presently having manufacturing facilities for key
 intermediates like 
 2,4-Dichloro-5-Fluoro Acetophenone (DCFA) (an intermediate for
 synthesizing quinolone 
 antibiotics like ciprofloxacin); Chlorohexanone (key intermediate in
 the manufacture of 
 cardio vascular medicine) and Methyl-4 (4-Chloro 1 oxo butane) a, a
 Di-Methyl Acetate (an
 intermediate in the manufacture of Fexofenadine an anti allergic
 drug). DCFA have 
 contributed 28.81% of our total sales during the nine months period
 ended December 31, 
 2007 whereas Methyl-4 (4-Chloro 1 oxo butane) a, a Di-Methyl Acetate
 contributed 24.54% 
 and Chlorohexanone contributed 8.95% of the total sales. 
 Our Company has a team of 25 chemists who are engaged in research and
 Our in-house R&D team has manpower to handle complex molecular
 synthesis and operations. 
 Our Company has presence in custom synthesis and contract research
 which encompasses 
 process development and scaling up technologies in pilot plants. Our
 in-house R&D facilities 
 are recognized by Government of India, Department of Scientific &
 Industrial Research (DSIR), 
 which is at present valid till March 31, 2010. With continuous focus
 on research & development, 
 our in-house R&D team has been able to develop process for some of
 APIs / intermediates viz.
 Diltiazem, Pentoxyfiline, Ciprofloxacin, Fexofenadine, Iopamidol and
 Our Company has also been granted ISO 9001:2000 Certificate of
 Assessment by AQA 
 International LLC with a scope of design development, manufacture and
 supply of organic and 
 inorganic intermediates which is valid till December 30, 2008.
 Our Company had started export of their products in the year 2002 to
 Israel followed by exports to 
 other countries like Italy, Japan, France, USA and Singapore.
 Currently, our exports comprise of 
 19.97% of our total turnover.
 History and major events
 Year              Event
 1996 -97        * Incorporation of Anus Laboratories Limited for
 manufacturing of Bulk Drug
                       * Started manufacturing in facility taken on
 leave and License basis.
                       * First Product manufactured -2,4 Dichloro 5
 Fluoro Acetophenone (DCFA)
 1998-99         * Purchased land, building, Plant & Machinery of a
 sick Unit through APSFC and
                           APIDC in a public bidding process
 2001-02         * Introduced another major drug intermediate viz.
                       * Granted subsidy of Rs. 7.90 lakhs from Andhra
 Pradesh Pollution Control Board
                           as incentive for implementing projects for
 recovery of by-products and for
                           showing our commitment towards Cleaner
 2002 -03        * Certified ISO 9001-2000 from AQA International to
 design development,
                            manufacture and supply of organic and
 inorganic intermediates
 2004-05         * Introduced another drug intermediate
 Methyl-4(4-Chloro 1-Oxo butyl) a, a Di
                           Methyl Phenyl Acetate
 2006-07         * Best Practices Award for Market penetration
 leadership from Frost and Sullivan
                           for the year 2005.
 -Anus Laboratories Ltd has  recommended a Final Dividend of 15%.
 -Anu's Laboratories has given the Bonus in the Ratio of 1:1
 -Company has splits its Face value of Shares from Rs 10 to Re 1
 Anu's Laboratories Ltd has informed BSE that the Company has acquired
  Stilbene Chemicals Ltd.
 - Anu's Laboratories Ltd has appointed Sri Chakravarthi Sundarashyam
 and Sri Ravindran Parthasarathy as Independent Directors on the
 Company's Board.
 -Company has changed its name from Anu's Laboratories Ltd to Ameya
 Laboratories Ltd.   
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • MARKET CUES : FIIs ने कैश में `637 Cr की खरीदारी की
  • MARKET CUES : DIIs ने कैश में `468 Cr की बिकवाली की
  • MARKET CUES : FIIs ने F&O में `2005 Cr की खरीदारी की
  • MARKET CUES : इंडेक्स फ्यूचर्स में `494 Cr की खरीदारी
  • MARKET CUES : इंडेक्स ऑप्शंस में `2119 Cr की खरीदारी
  • MARKET CUES : स्टॉक फ्यूचर्स में `596 Cr की बिकवाली
  • MARKET CUES : स्टॉक ऑप्शंस में `12 Cr की बिकवाली
  • CITI ON DLF : Sell रेटिंग, लक्ष्य `144/Sh
  • MS ON DLF : Overweight रेटिंग, लक्ष्य `211/Sh
  • CLSA ON DLF : Buy रेटिंग बरकरार, लक्ष्य `190/Sh

अभी देखें




(August 06, 2018)

AT (Rs)






Super Combo

Powerful mix of both trader and investor packs with timely expert advice.


Designed especially for traders looking to tap the profit opportunities of volatile markets.


For all investors looking to unearth stocks that are poised to move.